Intervention: CGI-1842
Trial phase: Phase 1 | Phase 2
SMILES: COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Patients going on the Pharmacodynamic study will receive JI-101 only.

JI-101: JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
Eligibility criteria:
Inclusion Criteria:

Male or female, ≥18 years of age
For the Pharmacokinetic Drug Interaction Study: Histologically or cytologically confirmed advanced solid tumors that are refractory to all standard of care therapy or for whom no standard therapy is available, or for whom other standard therapies the patient has denied. For the Pharmacodynamic Study: Histologically or cytologically confirmed metastatic/advanced ovarian carcinoma or metastatic/advanced KRAS mutant colorectal cancer or metastatic/advanced Head and neck squamous cell cancer (HNSCC) that are refractory to all standard therapies therapy or for whom no standard therapy is available, or for whom other standard therapies the patient has denied.
At least one measurable tumor as defined by RECIST
Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy
Eastern Cooperative Oncology Group (ECOG) of 0 to 2
Organ &marrow function as defined in the protocol.
No evidence of preexisting uncontrolled hypertension as documented by two baseline blood pressure readings taken at least 1 hour apart
Clinically euthyroid
Normal range cardiac function
For female patients of child-bearing potential, a negative serum pregnancy test at Screening.
Current use of an acceptable form of double-barrier birth control
Have provided written informed consent

Exclusion Criteria:

Known brain or other central nervous system metastases metastases that are not stable for 3 months or longer
Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation.
Major surgery, radiotherapy, chemotherapy, or cytokine therapy within 28 days of Study Day 0;
History of intratumoral bleeding or evidence of bleeding diathesis or coagulopathy
Female patients who are pregnant, planning a pregnancy, or who are breastfeeding
Known allergy or hypersensitivity to JI-101 or everolimus or any component of the investigational products
Use of an investigational drug/device/biologic within 28 days of Study Day 0
Current drug or alcohol abuse or history of drug or alcohol abuse within the past two years
Known history of or serologic positivity for the Hepatitis B Virus (HBV), or the Hepatitis C Virus (HCV), or for the human immunodeficiency virus (HIV)
History of cardiac abnormalities
Gastrointestinal (GI) abnormalities
Use of concomitant medications that prolong the QT/QTc interval within 14 days prior to Study Day 0
History of cerebrovascular accident including transient ischemic attack within the past 6 months
History of pulmonary embolism or deep vein thrombosis within the past 6 months
History of significant retinopathy or any progressive eye disease that could lead to severe loss of visual acuity or visual field loss during the study period
Treatment with heparin or heparin analogs
Inability or unwillingness to meet the requirements of the study
Other current active malignancy or history of malignancy within the past five years, except for cervical carcinoma in situ, basal cell carcinoma that has been surgically removed, or prostate cancer that is being managed with watchful waiting.
Any clinically significant abnormal finding at screening that the investigator judges would interfere with study participation